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Non-alcoholic fatty liver disease (NAFLD) in non-obese individuals is inadequately eluci-
dated. We aim to investigate the impact of known genetic polymorphisms on NAFLD and
the interaction between genetic risks and weight gain on NAFLD in obese and non-obese
Japanese individuals. A total of 1164 participants who received health checkups were
included. Participants with excessive alcohol consumption, with viral hepatitis or other inap-
propriate cases were excluded. Fatty liver was diagnosed by ultrasonography. Participants
with a body mass index (BMI) of <18.5 kg/m2, 18.5–22.9 kg/m2, 23.0–24.9 kg/m2 and25
kg/m2 were classified underweight, normal weight, overweight and obese, respectively.
Self-administered questionnaire for lifestyle was assessed and a total of 8 previously
reported genetic polymorphisms were chosen and examined. In all, 824 subjects were
enrolled. The overall prevalence of NAFLD was 33.0%: 0% in underweight, 15.3% in normal
weight, 41.1% in overweight and 71.7% in obese individuals. The prevalence of NAFLD is
more affected by the G allele of patatin-like phospholipase domain-containing protein 3
(PNPLA3) rs738409 in normal weight (odds ratio (OR) 3.52; 95%-CI: 1.42–8.71; P =
0.0063) and in overweight individuals (OR 2.60; 95%-CI: 1.14–5.91; P = 0.0225) than in
obese individuals (not significant). Moreover, the G allele of PNPLA3 rs738409 and weight
gain10 kg after age 20 had a joint effect on the risk of NAFLD in the normal weight (OR
12.00; 95% CI: 3.71–38.79; P = 3.3×10−5) and the overweight individuals (OR 13.40; 95%
CI: 2.92–61.36; P = 0.0008). The G allele of PNPLA3 rs738409 is a prominent risk factor for
NAFLD and the interaction between the PNPLA3 rs738409 and weight gain10 kg after
age 20 plays a crucial role in the pathogenesis of NAFLD, especially in non-obese Japa-
nese individuals.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is associated with the pathogenesis of nonalcoholic
steatohepatitis (NASH), liver cirrhosis and hepatocellular carcinoma and accompanies meta-
bolic syndromes such as type 2 diabetes (T2D), hypertension and dyslipidemia[1]. The preva-
lence of NAFLD increases in proportion to obesity, but in reality, this disease is not
uncommon in non-obese patients in East Asia [2, 3].
Recently, several reports have shown that the prevalence of NAFLD in a non-obese (BMI<
25.0) population was 18.4% in Japan [4], 12.6% in South Korea [5], and 7.2% in China [6].
Most recently, we also reported that the prevalence of NAFLD in non-obese participants at
health checkups was 15.2% [7]. Surprisingly, De la Cruz et al. reported that lean patients with
NAFLD have a higher overall mortality rate than overweight or obese patients with NAFLD
[8]. On the other hand, a previous review has demonstrated that ethnic differences or genetic
traits affect susceptibility to NAFLD [1]. By genome-wide association studies (GWAS), genes
associated with NAFLD have been determined [9, 10]. Of these, genetic polymorphisms in
patatin-like phospholipase domain-containing protein 3 (PNPLA3) rs738409 were shown to be
specifically associated with NAFLD [9, 10]. In East Asia, these polymorphisms have also been
demonstrated to be associated with NAFLD [11, 12].
Additionally, several gene variants other than those in PNPLA3 rs738409 have been
regarded as contributors to NAFLD [10]. While NAFLD in non-obese East Asians, including
Japanese, is striking compared with other ethnic groups, the impact of genetic factors on non-
obese NAFLD has not been clearly investigated. Moreover, a routine health checkup in Japan
typically includes a self-administered questionnaire provided by the Ministry of Health, Labor
andWelfare of Japan [13]. Our previous report [7] and a recent large-scale Japanese study [14]
revealed that the presence of weight gain10 kg after age 20 among the lifestyle information
in this questionnaire was a prominent risk factor for NAFLD even in non-obese Japanese
individuals.
Therefore, an evaluation of the genetic traits and the interaction between significant genetic
risk factors and weight gain10 kg after age 20 with respect to the pathogenesis of NAFLD in
non-obese Japanese individuals is required. Here, we conducted a cross-sectional study that
included Japanese participants who received health checkups at our hospital in Kyoto, Japan.
Materials and Methods
Ethics statement
Prior to sample collection, written informed consent was obtained from each participant for
the anonymous use of their data for an epidemiological study. The study design was approved
by the institutional review board of Kyoto Second Red Cross Hospital (No.S24-18) and Kyoto
Prefectural University of Medicine Ethical Review Board (No.G-129). The study was conducted
in accordance with the Declaration of Helsinki.
Study population and design
We included 1164 Japanese individuals aged 29–84 years who participated in health checkups,
including physical and physiological examinations, abdominal ultrasonography (US) and
blood screening examinations, during the period of September 2012 to March 2014 at Kyoto
Second Red Cross Hospital in Japan. Exclusion criteria were as follows: (1) inappropriate cases
(e.g., insufficient or indeterminate data); (2) hepatitis virus infection (i.e., hepatitis B surface
antigen-positive and hepatitis C virus antibody-positive); (3) the presence of autoimmune liver
disease; (4) ongoing treatment for thyroid disease; (5) ongoing hormone therapy; (6) excessive
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use of alcohol (210 g/week for males and140 g/week for females); (7) age34 and76
years. Finally, 824 participants aged 35–75 years who met the inclusion criteria were enrolled
(Fig 1). According to the Western Pacific Region of the WHO criteria that pertain to obesity
(WPRO criteria), the participants with a body mass index (BMI)<18.5 kg/m2 were classified
as underweight, those with a BMI of 18.5–22.9 kg/m2 were classified as normal weight, those
with a BMI of 23.0–24.9 kg/m2 were classified as overweight and those with a BMI25.0 kg/
m2 were classified as obese [15].
Physical examination and laboratory assessments
Body weight (BW) and height (Ht) were obtained for both sets of participants, and the BMI
was calculated. Waist circumference (WC) was measured by physicians at the level of the navel
when the participants were in a standing position. Venous blood samples were obtained from
all participants at 9AM following a 12-h overnight fast. The levels of aspartate aminotransfer-
ase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (GGT), total cho-
lesterol (TC), high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL)
cholesterol, triglycerides (TG), fasting plasma glucose (FPG) were measured using an auto-
mated analyzer with standard techniques. Additionally, we estimated the value of FIB4 index
which is considered a useful, simple and non-invasive marker for predicting hepatic fibrosis in
patients with NAFLD [16]. The value of the FIB4 index which is based on age, AST, ALT and
platelet counts were calculated in accordance with the established formula. Shah et al. proposed
that a low cut-off point (1.3) and a high cut-off point (2.67) of the FIB4 index are regarded as
the negative predictive value and the positive predictive value for detecting stage 3–4 advanced
fibrosis in patients with NAFLD, respectively [16].
Hypertension, type 2 diabetes (T2D) and dyslipidemia were diagnosed by the following cri-
teria: hypertension was considered present in patients on medication for hypertension and/or
in patients whose systolic blood pressure (SBP) was140 mmHg and/or in patients whose dia-
stolic blood pressure (DBP) was90 mmHg; T2D was considered present in patients on medi-
cation for T2D and/or when the FPG was126 mg/dl; dyslipidemia was considered present in
patients on medication for dyslipidemia and/or when the level of LDL cholesterol was140
mg/dl and/or when the level of TG was150 mg/dl and/or when the level of HDL cholesterol
was<40 mg/dl. According to the previous report [17], the normal range for ALT level was
30 U/l and ALT elevation was defined as level31 U/l.
DNA preparation and analysis
Genomic DNA was extracted from EDTA-blood from a blood sample using a DNeasy
Blood & Tissue Kit (QIAGEN, Tokyo, Japan). We selected 8 single nucleotide polymorphisms
(SNPs). We analyzed the genetic variations in the previously reported genes rs2228603 in neu-
rocan (NCAN), rs12137855 in lysophospholipase-like 1 (LYPLAL1), rs780094 in glucokinase
regulatory protein (GCKR) and rs4240624 in protein phosphatase 1, regulatory subunit 3b
(PPP1R3B) with real-time amplification by sequence-specific primers (S1 Table) and melting
curve analysis using a Light Cycler Instrument [10].
The primer pairs were used for the amplification of the NCAN, LYPLAL1, GCKR and
PPP1R3B genes. The sensor probes were labeled with 3´-fluorescein, and the anchor probes
were labeled with 5´-LightCycler Red-640. The PCR mixture was prepared using the Light
Cycler Fast Start DNAMaster Hybridization Probes (Roche Applied Science, Indianapolis, IN,
USA). Genotyping for rs1004467 in cytochrome P450, family 17, subfamily A, polypeptide 1
(CYP17A1), rs11191548 in 5’-nucleotidase, cytosolic II (NT5C2), rs6810075 in adiponectin
(ADIPOQ) and rs738409 in PNPLA3 was completed using the TaqMan SNP genotyping assay
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(Applied Biosystems, Foster City, CA, USA) with commercially available pre-designed SNP-
specific primers for PCR amplification and extension reactions according to the manufacturer’s
protocol [9,10, 18, 19].
Abdominal US protocol and the definition of fatty liver
All subjects received an abdominal US to assess the liver. The liver parenchyma in all partici-
pants was examined using a conventional convex array transducer. The presence of fatty
change was defined as an increased echogenicity of the liver parenchyma compared with the
renal parenchyma (bright liver and liver-kidney contrast), deep US attenuation in the right
lobe of the liver (deep attenuation) and/or poor visualization of the hepatic vein (vascular blur-
ring) [7, 20]. The abdominal US was performed by experienced sonographers with a Xario unit
with a 3.5-MHz convex array transducer (Toshiba Medical Systems, Tokyo, Japan). The tech-
nical parameters were adjusted for each participant using the standard protocol for US. Four
board-certified gastroenterologists of the Japanese Society of Gastroenterology reviewed the
images and made a diagnosis.
Questionnaire
Lifestyle was assessed using a self-administered questionnaire provided by the Health Depart-
ment of the Ministry of Health, Labor and Welfare in Japan [13] that properly included infor-
mation about disease history and various lifestyle habits (S2 Table). The information from the
questionnaire was confirmed during an interview with a physician [7].
Statistical analysis
The enrolled subjects were categorized into 4 groups according to BMI, as mentioned above,
and were assessed [15]. Descriptive statistics (means and standard deviations) were calculated
for all continuous variables. Differences between 2 groups were assessed using the Mann–
Whitney U test or the chi square test. Differences between 3 or more groups were assessed
using the chi square test with Bonferroni multiple testing correction. The Mann–Whitney U
test was used for continuous variables, and the chi square test was used for categorical
variables.
We compared the risk between specific allele carriers and non-carriers. In addition, as the A
allele of CYP17A1 rs1004467 and the T allele of NT5C2 rs11191548 are associated with a
reduced visceral fat area (VFA) and a reduced subcutaneous fat area (SFA) [18], the G allele of
CYP17A1 rs1004467 and the C allele of NT5C2 rs11191548 were considered risk factors for
VFA and SFA. The risk allele frequencies were calculated, and the Hardy-Weinberg equilib-
rium was examined using the chi square test. Univariate and multivariate logistic regression
analyses were performed to identify the variables that are risk factors for NAFLD.
Model 1 aimed to identify the significant factors that are associated with NAFLD among the
genetic polymorphisms included in this study. After adjusting for age and gender, only the sig-
nificant covariates among them were calculated. Model 2 aimed to identify the independent
predictors of NAFLD among these polymorphisms and clinical parameters. In addition to the
age and gender, known metabolic traits such as hypertension, T2D, dyslipidemia and weight
gain10 kg after age 20, are strong predictors of NAFLD among the self-reported lifestyle
items in line with the previous reports [7, 14]; these were therefore taken into account during
Fig 1. Flowchart of the inclusion and exclusion criteria.HBV, hepatitis B virus; HCV, hepatitis C virus;
NT5C2, 5’-nucleotidase, cytosolic II; ADIPOQ, adiponectin.
doi:10.1371/journal.pone.0140427.g001
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the analysis. Furthermore, these genetic polymorphisms, age, gender, metabolic traits and ALT
elevation (31 U/l) were examined in Model 3 because ALT was a significant factor for
NAFLD in the univariate analysis.
Parameters with effects at P<0.05 were entered into the stepwise multivariate logistic
regression analysis with P<0.05 for inclusion and P0.05 for exclusion. Values of P<0.05
were considered statistically significant. The statistical analysis was performed using SPSS sta-
tistical software version 17.0 (SPSS, Chicago, IL, USA).
Results
Clinical features of the study population
Of the 1164 participants, 340 cases were excluded, and finally, 824 cases who fulfilled the crite-
ria were enrolled. Of these, the mean age was 54.3 years. A total of 548 cases (66.5%) were
male, 276 cases (33.5%) were female, 198 cases (24.0%) were obese and 272 cases (33.0%) were
diagnosed with NAFLD. The demographic, clinical, metabolic features of these cases are sum-
marized in S3 Table and the genetic variations of these cases are summarized in Table 1. No
cases of NAFLD occurred in individuals considered underweight (BMI<18.5). The prevalence
of NAFLD was 15.3% in the normal weight (BMI 18.5–22.9) group, 41.1% in the overweight
(BMI 23.0–24.9) group and 71.7% in the obese (BMI25.0) group.
Taken together, the prevalence was 20.7% in the non-obese (BMI24.9) population. The
prevalence was higher in males than in females in all groups. A significant difference was
observed in the values of WC, AST, ALT, GGT, TG, HDL and FPG and in the proportion of
weight gain10 kg after age 20 between individuals with NAFLD and those with non-
NAFLD, regardless of the group. The distributions of each genetic polymorphism in all partici-
pants were in Hardy-Weinberg equilibrium and were statistically similar to the distribution
found in a Japanese population that was included in the International HapMap Project.
The association between genetic polymorphisms, metabolic traits and
NAFLD
By univariate analysis, crude odds ratios (ORs) of these factors in the 4 groups were determined
and are shown in Table 2. TT homozygotes of LYPLAL1 rs12137855 were very rare and there
was no GG homozygote of PPP1R3B rs4240624. Consequently, the ORs for LYPLAL1
rs12137855 in the normal and in the overweight groups and those for PPP1R3B rs4240624 in
all groups were unable to be calculated statistically.
The predictors of NAFLD as determined by stepwise multivariate logistic regression analysis
are shown in Tables 3, 4 and 5. In Model 1, CYP17A1 rs1004467 and PNPLA3 rs738409 were
predictors of NAFLD in the individuals of normal weight independently of age and gender.
PNPLA3 rs738409 was a predictor in overweight individuals (Table 3).
In Model 2, gender, PNPLA3 rs738409, hypertension, dyslipidemia and weight gain10 kg
after age 20 were the independent predictors in the patients with normal weight. Likewise, gen-
der, PNPLA3 rs738409 and weight gain10 kg after age 20 were independent predictors in the
patients who were overweight. Gender, hypertension, dyslipidemia and weight gain10 kg
after age 20 were also independent predictors in obese individuals (Table 4).
In Model 3, gender, PNPLA3 rs738409, dyslipidemia, weight gain10 kg after age 20 and
ALT elevation were the independent predictors in patients with normal weight. Likewise, gen-
der, PNPLA3 rs738409 and weight gain10 kg after age 20 were independent predictors in the
patients who were overweight. Age and ALT elevation were also independent predictors in
obese individuals (Table 5).
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Table 1. The genetic polymorphisms of NAFLD and non-NAFLD.
Underweight (BMI<18.5) (n = 65)
Non-NAFLD (n = 65)
Variables Allele Genotype RA + vs—(%)
(RAF)
NCAN C/T* 56/9/0 86.2/13.8
(0.0692)
LYPLAL1 C*/T 54/0/1 98.2/1.8
(0.9076)
GCKR C/T* 12/36/17 18.5/81.5
(0.5384)
PPP1R3B A*/G 63/2/0 100.0/0.0
(0.9846)
CYP17A1 A/G* 31/26/8 47.7/52.3
(0.3230)
NT5C2 C*/T 7/20/38 41.5/58.5
(0.2615)
ADIPOQ C/T* 13/33/19 20.0/80.0
(0.5461)
PNPLA3 C/G* 20/36/9 30.8/69.2
(0.4153)
Normal weight (BMI 18.5–22.9) (n = 391)
NAFLD (n = 60) Non-NAFLD (n = 331)
Variables Allele Genotype RA + vs—(%) Genotype RA + vs—(%) P-value
(RAF) (RAF)
NCAN C/T* 51/9/0 85.0/15.0 297/33/1 89.7/10.3 0.2682
(0.0750) (0.0528)
LYPLAL1 C*/T 49/11/0 100.0/0.0 294/36/1 99.7/0.3 1.0000
(0.9083) (0.9425)
GCKR C/T* 10/28/22 16.7/83.3 59/157/115 17.8/82.2 0.8285
(0.6000) (0.5845)
PPP1R3B A*/G 58/2/0 100.0/0.0 324/7/0 100.0/0.0 1.0000
(0.9833) (0.9894)
CYP17A1 A/G* 22/32/6 36.7/63.3 162/127/42 48.9/51.1 0.0796
(0.3666) (0.3187)
NT5C2 C*/T 5/26/29 51.7/48.3 31/122/178 46.2/53.8 0.4370
(0.3000) (0.2779)
ADIPOQ C/T* 18/21/21 30.0/70.0 73/180/78 22.0/78.0 0.1802
(0.5250) (0.5075)
PNPLA3 C/G* 7/33/20 11.7/88.3 95/174/62 28.7/71.3 0.0057
(0.6083) (0.4501)
Overweight (BMI 23.0–24.9) (n = 170)
NAFLD (n = 70) Non-NAFLD (n = 100)
Variables Allele Genotype RA + vs—(%) Genotype RA + vs—(%) P-value
(RAF) (RAF)
NCAN C/T* 64/6/0 91.4/8.6 94/6/0 94.0/6.0 0.5543
(0.0428) (0.0300)
LYPLAL1 C*/T 60/9/1 98.6/1.4 88/12/0 100.0/0.0 0.4117
(0.9214) (0.9400)
(Continued)
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In total (n = 824), independently of age and gender, PNPLA3 rs738409 was a predictor
(adjusted OR = 1.73, 95%CI: 1.20–2.48, P = 0.0027) in Model 1. In Model 2, weight gain10
kg after age 20 (adjusted OR = 6.82, 95%CI: 4.81–9.65, P = 2.6×10−27), gender (adjusted
OR = 3.12, 95%CI: 2.06–4.72, P = 6.9×10−8), dyslipidemia (adjusted OR = 2.14, 95%CI: 1.50–
3.05, P = 2.1×10−5), PNPLA3 rs738409 (adjusted OR = 1.91, 95%CI: 1.26–2.88, P = 0.0019) and
hypertension (adjusted OR = 1.71, 95%CI: 1.18–2.50, P = 0.0046) were independent predictors
for NAFLD. In Model 3, weight gain10 kg after age 20 (adjusted OR = 5.65, 95%CI: 3.93–
8.13, P = 9.1×10−21), ALT elevation (adjusted OR = 5.31, 95%CI: 3.34–8.45, P = 1.7×10−12),
gender (adjusted OR = 2.60, 95%CI: 1.69–3.99, P = 1.3×10−5), dyslipidemia (adjusted
Table 1. (Continued)
GCKR C/T* 10/34/26 14.3/85.7 16/58/26 16.0/84.0 0.7598
(0.6142) (0.5500)
PPP1R3B A*/G 68/2/0 100.0/0.0 100/0/0 100.0/0.0 1.0000
(0.9857) (1.0000)
CYP17A1 A/G* 34/30/6 48.6/51.4 44/46/10 44.0/56.0 0.5560
(0.3000) (0.3300)
NT5C2 C*/T 5/25/40 42.9/57.1 7/38/55 45.0/55.0 0.7818
(0.2500) (0.2600)
ADIPOQ C/T* 18/26/26 25.7/74.3 22/53/25 22.0/78.0 0.5741
(0.5571) (0.5150)
PNPLA3 C/G* 10/38/22 14.3/85.7 34/48/18 34.0/66.0 0.0038
(0.5857) (0.4200)
Obese (BMI >25.0) (n = 198)
NAFLD (n = 142) Non-NAFLD (n = 56) P-value
Variables Allele Genotype RA + vs—(%) Genotype RA + vs—(%)
(RAF) (RAF)
NCAN C/T* 125/17/0 88.0/12.0 52/4/0 92.9/7.1 0.4441
(0.0598) (0.0357)
LYPLAL1 C*/T 125/16/1 99.3/0.7 46/9/1 98.2/1.8 0.4866
(0.9366) (0.9017)
GCKR C/T* 21/76/45 14.8/85.2 10/33/13 17.9/82.1 0.6647
(0.5845) (0.5267)
PPP1R3B A*/G 139/3/0 100.0/0.0 54/2/0 100.0/0.0 1.0000
(0.9894) (0.9821)
CYP17A1 A/G* 56/66/20 39.4/60.6 17/33/6 30.4/69.6 0.2330
(0.3732) (0.4017)
NT5C2 C*/T 13/65/64 54.9/45.1 5/23/28 50.0/50.0 0.5310
(0.3204) (0.2946)
ADIPOQ C/T* 40/61/41 28.2/71.8 21/23/12 37.5/62.5 0.2002
(0.5035) (0.4196)
PNPLA3 C/G* 37/71/34 26.1/73.9 21/26/9 37.5/62.5 0.1110
(0.4894) (0.3928)
RAF, risk allele frequency; BMI, body mass index; RA + vs -, carriers of the risk allele versus non-carriers; NCAN, neurocan; LYPLAL1,
lysophospholipase-like 1; GCKR, glucokinase regulatory protein; PPP1R3B, protein phosphatase 1, regulatory subunit 3b; CYP17A1, cytochrome P450,
family 17, subfamily A, polypeptide 1; NT5C2, 5’-nucleotidase, cytosolic II, ADIPOQ, adiponectin; PNPLA3, patatin-like phospholipase domain-containing
protein 3. The risk allele of each SNP is marked by an asterisk. P-values were calculated with the chi square test for categorical variables. P-values for
the genetic polymorphisms show the difference between carriers of the risk allele and non-carriers.
doi:10.1371/journal.pone.0140427.t001
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Table 2. The association between genetic polymorphisms, metabolic traits and the risk of NAFLD.
Normal weight(BMI 18.5–22.9)(n = 391)
Variables P-value Crude OR (95%CI)
Age (years) 0.1123 1.02 (0.99–1.04)
Gender (male) 0.0009 3.18(1.59–6.34)
NCAN [T] 0.2844 1.54 (0.69–3.40)
LYPLAL1 [C] - -
GCKR [T] 0.8286 1.08 (0.52–2.26)
PPP1R3B [A] - -
CYP17A1 [G] 0.0816 1.65 (0.93–2.92)
NT5C2 [C] 0.4375 1.24 (0.71–2.15)
ADIPOQ [T] 0.1823 0.66 (0.35–1.21)
PNPLA3 [G] 0.0079 3.04 (1.33–6.94)
Hypertension 0.0054 2.33 (1.28–4.24)
T2D 0.0522 2.71 (0.99–7.45)
Dyslipidemia 1.1×10−4 3.22(1.78–5.83)
Weight gain 10 kg after age 20 6.9×10−5 3.68 (1.93–7.00)
ALT elevation 1.1×10−6 6.32 (3.00–13.30)
Overweight (BMI 23.0–24.9) (n = 170)
Variables P-value Crude OR (95%CI)
Age (years) 0.7076 0.99 (0.96–1.02)
Gender (male) 0.0010 4.79 (1.87–12.24)
NCAN [T] 0.5214 1.46 (0.45–4.75)
LYPLAL1 [C] - -
GCKR [T] 0.7599 1.14 (0.48–2.69)
PPP1R3B [A] - -
CYP17A1 [G] 0.5562 0.83 (0.45–1.53)
NT5C2 [C] 0.7818 0.91 (0.49–1.69)
ADIPOQ [T] 0.5745 0.81 (0.39–1.66)
PNPLA3 [G] 0.0049 3.09 (1.40–6.79)
Hypertension 0.6719 0.87 (0.45–1.65)
T2D 0.3740 1.84 (0.47–7.13)
Dyslipidemia 0.0760 1.78 (0.94–3.38)
Weight gain 10 kg after age 20 0.0032 2.60 (1.37–4.91)
ALT elevation 0.0025 3.36 (1.53–7.37)
Obese (BMI >25.0) (n = 198)
Variables P-value Crude OR (95%CI)
Age (years) 0.2371 1.02 (0.98–1.05)
Gender (male) 0.0506 2.04 (0.99–4.16)
NCAN [T] 0.3256 1.76 (0.56–5.50)
LYPLAL1 [C] 0.5082 2.56 (0.15–41.70)
GCKR [T] 0.5930 1.25 (0.54–2.86)
PPP1R3B [A] - -
CYP17A1 [G] 0.2344 0.66 (0.34–1.29)
NT5C2 [C] 0.5313 1.21 (0.65–2.26)
ADIPOQ [T] 0.2017 1.53 (0.79–2.94)
PNPLA3 [G] 0.1129 1.70 (0.88–3.28)
Hypertension 0.0115 2.53 (1.23–5.20)
T2D 0.0467 3.05 (1.01–9.16)
(Continued)
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OR = 1.98, 95%CI: 1.37–2.87, P = 0.0002), PNPLA3 rs738409 (adjusted OR = 1.98, 95%CI:
1.28–3.04, P = 0.0019) and hypertension (adjusted OR = 1.62, 95%CI: 1.09–2.40, P = 0.0156)
were independent predictors for NAFLD.
The values of the FIB4 index and the prevalence of an FIB4 index low cut-off index (<1.3),
indeterminate (1.3–2.67) and high cut-off index (>2.67) was shown in S3 Table. Furthermore,
we analyzed the association between the values of the FIB4 index and the PNPLA3 rs738409
genetic polymorphism in patients with NAFLD. From the results, the FIB4 index was not sig-
nificantly associated with PNPLA3 rs738409 genetic polymorphism in total, in normal weight,
in overweight and in obese groups, respectively (data not shown).
The joint effect of the PNPLA3 rs738409 variant and weight gain10 kg
after age 20 on NAFLD
The prevalence of NAFLD was significantly higher in carriers of the G risk allele in PNPLA3
rs738409 than in non-carriers without weight gain10 kg after age 20 in the normal weight
and overweight groups (Fig 2A and 2B). The prevalence of NAFLD did not differ between
carriers of the G risk allele and non-carriers with weight gain10 kg after age 20, regardless
of the group (Fig 2A–2C). The highest prevalence of NAFLD was observed in the carriers of
the G risk allele with weight gain10 kg after age 20 in all groups (Fig 2A–2C). The lowest
Table 2. (Continued)
Dyslipidemia 0.0262 2.03 (1.08–3.82)
Weight gain 10 kg after age 20 0.0084 2.88 (1.31–6.33)
ALT elevation 2.3×10−6 10.49 (3.95–27.83)
OR: odds ratio, CI: confidence interval.
NCAN, neurocan; LYPLAL1, lysophospholipase-like 1; GCKR, glucokinase regulatory protein; PPP1R3B,
protein phosphatase 1, regulatory subunit 3b; CYP17A1, cytochrome P450, family 17, subfamily A,
polypeptide 1; NT5C2, 5’-nucleotidase, cytosolic II, ADIPOQ, adiponectin; PNPLA3, patatin-like
phospholipase domain-containing protein 3; T2D, type 2 diabetes. The risk allele of each SNP is shown in
brackets. Metabolic traits include hypertension, T2D, dyslipidemia and weight gain 10 kg after age 20.
doi:10.1371/journal.pone.0140427.t002
Table 3. The association between genetic polymorphisms and the risk of NAFLD. (Model 1).
Normal weight (BMI 18.5–22.9) (n = 391)
Variables P-value Adjusted OR (95%CI)
Age (years) 0.0103 1.03 (1.00–1.06)
Gender (male) 2.4×10−4 3.86 (1.87–7.94)
CYP17A1 [G] 0.0462 1.82 (1.01–3.29)
PNPLA3 [G] 0.0073 3.15 (1.36–7.31)
Overweight (BMI 23.0–24.9) (n = 170)
Variables P-value Adjusted OR (95%CI)
Gender (male) 0.0023 4.38 (1.69–11.36)
PNPLA3 [G] 0.0131 2.78 (1.24–6.26)
OR: odds ratio, CI: confidence interval.
CYP17A1, cytochrome P450, family 17, subfamily A, polypeptide 1; PNPLA3, patatin-like phospholipase
domain-containing protein 3. The risk allele of each SNP is shown in brackets. Age, gender and the genetic
polymorphisms were examined in Model 1.
doi:10.1371/journal.pone.0140427.t003
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prevalence was observed in non-carriers without weight gain10 kg after age 20 in the normal
weight and overweight groups (Fig 2A and 2B).
In addition, non-carriers without weight gain10 kg after age 20 were considered the refer-
ence group, and the crude OR was assessed using logistic regression analysis. Compared with
the reference group, the G risk allele carriers with weight gain10 kg after age 20 had ORs of
12.00 in the normal weight group and 13.40 in the overweight group (Table 6).
Discussion
The highlight of this study is that the prevalence of NAFLD is more affected by PNPLA3
rs738409 polymorphism in non-obese individuals than in obese individuals. In other words,
whereas obesity is itself a stronger risk factor for NAFLD, the G risk allele carriers may have a
significantly increased risk for NAFLD in case they are non-obese. In addition, the hereditary
factor PNPLA3 rs738409 confers a susceptibility to NAFLD in combination with an acquired
factor weight gain in adulthood in non-obese individuals.
In East Asia, NAFLD in non-obese populations has been a matter of concern [2, 3]. Accord-
ing to a recent review, the prevalence of NAFLD in non-obese Asians is approximately 11–21%
[3], and therefore, the result of this study was in agreement with this review. Recently, GWAS
determined that genetic polymorphisms in PNPLA3 rs738409 are associated with NAFLD even
after the results were adjusted for BMI and metabolic values [9, 10]. The majority of Hispanic
people carry the risk allele of G in PNPLA3 rs738409 [9, 21, 22]. As for East Asia, these poly-
morphisms were also shown to be associated with NAFLD in Japanese, Taiwanese and Chinese
individuals [11, 12, 23, 24]. In reality, the G risk allele frequency is 0.34 in Han Chinese, 0.44 in
Table 4. The association between genetic polymorphisms, metabolic traits and the risk of NAFLD.
(Model 2).
Normal weight (BMI 18.5–22.9) (n = 391)
Variables P-value Adjusted OR (95%CI)
Gender (male) 0.0019 3.16 (1.52–6.55)
PNPLA3 [G] 0.0112 3.07 (1.29–7.30)
Hypertension 0.0314 2.03 (1.06–3.87)
Dyslipidemia 5.2×10−4 3.02 (1.61–5.64)
Weight gain 10 kg after age 20 0.0059 2.62 (1.32–5.23)
Overweight (BMI 23.0–24.9) (n = 170)
Variables P-value Adjusted OR (95%CI)
Gender (male) 0.0052 3.94 (1.50–10.32)
PNPLA3 [G] 0.0225 2.60 (1.14–5.91)
Weight gain 10 kg after age 20 0.0170 2.25 (1.15–4.40)
Obese (BMI >25.0) (n = 198)
Variables P-value Adjusted OR (95%CI)
Gender (male) 0.0386 2.23 (1.04–4.77)
Hypertension 0.0117 2.63 (1.23–5.58)
Dyslipidemia 0.0342 2.04 (1.05–3.96)
Weight gain 10 kg after age 20 0.0136 2.82 (1.23–6.45)
OR: odds ratio, CI: confidence interval.
PNPLA3, patatin-like phospholipase domain-containing protein 3; T2D, type 2 diabetes. The risk allele of
each SNP is shown in brackets. Metabolic traits include hypertension, T2D, dyslipidemia and weight gain
10 kg after age 20. Age, gender, the genetic polymorphisms, hypertension, T2D, dyslipidemia and weight
gain 10 kg after age 20 were examined in Model 2.
doi:10.1371/journal.pone.0140427.t004
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Japanese healthy controls, 0.60 in Japanese NAFLD patients, 0.22 in European, and 0.12 in
African [9, 10, 25]. In the Korean study population, the G risk allele frequency is 0.45 in the
healthy controls and 0.56 in NAFLD patients [26]. Therefore, higher frequency of the G allele
in PNPLA3 rs738409 may confer much susceptibility to NAFLD in non-obese individuals espe-
cially in Eastern Asians compared with Europeans and Africans. The mechanism how PNPLA3
rs738409 gene variation affects susceptibility to NAFLD in non-obese individuals has not yet
been completely elucidated. According to the previous reports, the PNPLA3 rs738409 variant
may affect susceptibility to NAFLD via some plausible mechanisms, including impairment of
intrahepatocellular lipolysis [27], lipid droplets remodeling [28], very low-density lipoprotein
(VLDL) secretion [29], and retinol metabolism via retinyl-palmitate lipase activity [30] and the
G risk allele in PNPLA3 rs738409 is a risk factor for NAFLD, especially in subjects without
metabolic syndrome [31]. Altogether, considering the relatively high frequency of G risk allele
in PNPLA3 rs738409 in Japanese, we suggested that the PNPLA3 rs738409 polymorphism may
play a significant role in NAFLD in non-obese Japanese individuals.
As previously described in a meta-analysis, a PNPLA3 rs738409 variant was associated with
the severity of NAFLD in populations across the world [32] and with the development of
advanced hepatic fibrosis in Japanese [24]. Shen et al. reported that NAFLD patients carrying
PNPLA3 rs738409 GG genotype have more sensitivities to the interventional effects of lifestyle
modification [33]. Consequently, considering the high mortality of lean patients with NAFLD
[8], public information to help people avoid weight gain in adulthood in order to prevent
NAFLD in non-obese populations is important.
In this study, the genetic polymorphisms of NCAN rs2228603, GCKR rs780094, PPP1R3B
rs4240624 and LYPLAL1 rs12137855 were not associated with NAFLD in contrast to the
results of previous European and American studies [21, 22]. As for GCKR rs780094, East
Table 5. The association between genetic polymorphisms, metabolic traits, ALT elevation and the
risk of NAFLD. (Model 3).
Normal weight (BMI 18.5–22.9) (n = 391)
Variables P-value Adjusted OR (95%CI)
Gender (male) 0.0101 2.62 (1.25–5.49)
PNPLA3 [G] 0.0063 3.52 (1.42–8.71)
Dyslipidemia 0.0007 2.99 (1.58–5.68)
Weight gain 10 kg after age 20 0.0042 2.79 (1.38–5.65)
ALT elevation 5.5×10−5 5.29 (2.35–11.90)
Overweight (BMI 23.0–24.9) (n = 170)
Variables P-value Adjusted OR (95%CI)
Gender (male) 0.0052 3.94 (1.50–10.32)
PNPLA3 [G] 0.0225 2.60 (1.14–5.91)
Weight gain 10 kg after age 20 0.0170 2.25 (1.15–4.40)
Obese (BMI >25.0) (n = 198)
Variables P-value Adjusted OR (95%CI)
Age 0.0111 1.05 (1.01–1.09)
ALT elevation 4.3×10−7 13.80 (4.98–38.20)
OR: odds ratio, CI: confidence interval.
PNPLA3, patatin-like phospholipase domain-containing protein 3; T2D, type 2 diabetes. The risk allele of
each SNP is shown in brackets. Metabolic traits include hypertension, T2D, dyslipidemia and weight gain
10 kg after age 20. Age, gender, the genetic polymorphisms, hypertension, T2D, dyslipidemia, weight
gain 10 kg after age 20 and ALT elevation were examined in Model 3.
doi:10.1371/journal.pone.0140427.t005
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Asians studies have shown that this genotype was associated with NAFLD [24, 34, 35, 36]. Tan
et al. demonstrated that the association between GCKR rs780094 and NAFLD is significant in
the Indians but not significant in Malays and Chinese [37]. One recent meta-analysis including
2091 NAFLD patients and 3003 normal controls indicated that GCKR rs780094 is significantly
associated with NAFLD in both Asians and other ethnicity [38]. Therefore, further examina-
tions are necessary to determine whether this discrepancy is explained by ethnicity or the sam-
ple size of the study population.
Interestingly, CYP17A1 rs1004467 was mildly associated with NAFLD in normal weight
individuals. CYP17A1 gene encodes a key enzyme in the metabolism of steroid which influ-
ences hypertension, VFA and SFA in Japanese women [18]. A previous report suggested that
visceral fat accumulation is an important factor in the development of NAFLD in Japanese
Fig 2. The interaction between the G risk allele in PNPLA3 rs738409 and weight gain10 kg after age 20 on the prevalence of NAFLD according to
group. The normal weight group (A), the overweight group (B), and the obese group (C) are shown, respectively. The relative percentage of NAFLD is shown
for each group. Differences between the groups were calculated using the chi square test. After Bonferroni multiple testing correction, values of P <0.0083
were considered statistically significant and were marked with an asterisk. The risk allele of PNPLA3 rs738409 is enclosed in brackets.
doi:10.1371/journal.pone.0140427.g002
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individuals [39]. Taken together, we suggest that CYP17A1 rs1004467 is involved in the patho-
genesis of NAFLD via visceral fat accumulation in a Japanese population of normal weight. To
our knowledge, there is no article that describes the association between CYP17A1 rs1004467
and NAFLD, so further research will be necessary in the future.
Several limitations of this study are noted. First, fatty liver was diagnosed by US. US is cur-
rently the most common method for assessing hepatic steatosis [40], whereas it is insensitive to
hepatic steatosis when there is<20% fat [41]. Although liver biopsy is the gold standard for the
diagnosis of NAFLD, it is not suitable from a safety standpoint at health checkups. Proton mag-
netic resonance spectroscopy is not practical for a financial reason [40]. Second, a majority of
the participants are likely vigilant with regard to their health [42], the possibility of examinee
bias cannot be denied. Third, nutritional intake is linked with fatty liver [43, 44], but the assess-
ment of diet was not included in the questionnaire given during routine checkups [13]. Fourth,
information on insulin resistance was unavailable in this study, although it has been closely
linked to NAFLD [5, 39, 45]. Currently, an insulin resistance marker such as the homeostasis
model assessment ratio (HOMA-R) is not investigated in routine checkups. Lastly, this study
did not support the previous report which indicated the linkage between the PNPLA3
rs738409 genetic polymorphism and advanced hepatic fibrosis in patients with NAFLD [24].
The values of FIB4 index were low in this study, and so we suggested that there were few
patients with severe NASH at our health checkup compared with the hospital based study [24].
In summary, these findings have demonstrated the novel idea that PNPLA3 rs738409 may
robustly affect the pathogenesis of NAFLD in non-obese individuals compared with obese indi-
viduals and may have an additive joint effect along with changes in lifestyle such as weight gain
10 kg after age 20. Further investigations are required to elucidate the clinical significance of
the genetic influences on NAFLD in non-obese populations across East Asia.
Table 6. The association between the G risk allele in PNPLA3 rs738409, weight gain10 kg after age
20 and the risk of NAFLD.
Normal weight (BMI 18.5–22.9) (n = 391)
Category P-value Crude OR (95%CI)
PNPLA3 [G]- Weight gain- - 1.00 (Reference)
PNPLA3 [G]+ Weight gain- 0.0121 3.88 (1.34–11.23)
PNPLA3 [G]- Weight gain+ 0.0133 8.15 (1.54–43.02)
PNPLA3 [G]+ Weight gain+ 3.3×10−5 12.00 (3.71–38.79)
Overweight (BMI 23.0–24.9) (n = 170)
Category P-value Crude OR (95%CI)
PNPLA3 [G]- Weight gain- - 1.00 (Reference)
PNPLA3 [G]+ Weight gain- 0.0151 6.79 (1.44–31.89)
PNPLA3 [G]- Weight gain+ 0.0217 7.33 (1.33–40.20)
PNPLA3 [G]+ Weight gain+ 0.0008 13.40 (2.92–61.36)
Obese (BMI>25.0) (n = 198)
Category P-value Crude OR (95%CI)
PNPLA3 [G]- Weight gain- - 1.00 (Reference)
PNPLA3 [G]+ Weight gain- 0.4177 0.46 (0.07–2.99)
PNPLA3 [G]- Weight gain+ 0.8771 0.86 (0.14–5.19)
PNPLA3 [G]+ Weight gain+ 0.4045 2.11 (0.36–12.28)
OR: odds ratio, CI: confidence interval, PNPLA3: patatin-like phospholipase domain-containing protein 3,
Weight gain: weight gain 10 kg after age 20. The risk allele is shown in brackets.
doi:10.1371/journal.pone.0140427.t006
PNPLA3 rs738409 Impact on NAFLD in the Non-Obese
PLOS ONE | DOI:10.1371/journal.pone.0140427 October 20, 2015 14 / 17
Supporting Information
S1 Table. SNP-specific primers and probes for PCR amplification. NCAN, neurocan;
LYPLAL1, lysophospholipase-like 1; GCKR, glucokinase regulatory protein; PPP1R3B, protein
phosphatase 1.
(DOCX)
S2 Table. Questionnaire for a specific health checkup in Japan.
(DOCX)
S3 Table. The demographic, clinical and metabolic features of NAFLD and non-NAFLD.
BMI, body mass index; WC, Waist circumference; SBP, systolic blood pressure; DBP, diastolic
blood pressure; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT,
gamma-glutamyl transpeptidase; TC, total cholesterol; TG, triglyceride; HDL, high density
lipoprotein- cholesterol; LDL, low density lipoprotein-cholesterol; FPG, fasting plasma glucose;
T2D, type 2 diabetes. Continuous values are expressed as the means ±SD. P-values were calcu-
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